Relevant bibliographies by topics / Novel drug delivery system

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Novel drug delivery system'

Author: Grafiati
Published: 18 May 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Novel drug delivery system.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Novel drug delivery system"

1

SHARMA, PRASHANT. "Pulsatile Drug Delivery System – A Novel Approach for Time and Spatial Controlled Drug Delivery." Journal of Pharmaceutical Technology, Research and Management 4, no. 1 (May 2, 2016): 13–29. http://dx.doi.org/10.15415/jptrm.2016.41002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

S, Harish, and Bhuvana K. "Niosomes: A novel drug delivery system and its Therapeutic uses." JOURNAL OF CLINICAL AND BIOMEDICAL SCIENCES 9, no. 2 (June 15, 2019): 31–33. http://dx.doi.org/10.58739/jcbs/v09i2.8.

Full text
Abstract:
Administration of medications to specific targets with minimal affinity to other organs is a challenge during treatment of disease conditions. Drug-delivery systems which are Target-specific enable the localization of drugs to their site of action. These Targeted drug delivery systems utilize various carriers, such as serum proteins, liposomes, synthetic polymers, and microspheres. Niosomes, are a type of drug delivery system which has a bilayer structure made of non-ionic surfactants. Nio-somes are amphiphilic hence they can encapsulate both lipophilic or lipophobic drugs and increase their bioavailability. This review describes the structure, methods of preparation and applications of niosomes in various diseases. Keyword: Niosomes, Drug Delivery, Therapeutic Uses
APA, Harvard, Vancouver, ISO, and other styles
3

Ankit Kumar and Sanjeev Kumar. "Intra Vaginal Drug Delivery System (Novel Drug Delivery System)." International Journal for Research in Applied Sciences and Biotechnology 7, no. 6 (December 26, 2020): 234–41. http://dx.doi.org/10.31033/ijrasb.7.6.33.

Full text
Abstract:
In case of intra-vaginal route of drug administration the dosage form is applied vaginally for the convenient release of the dosage form and for better therapeutic action of the medicament, it is usually used in HIV patients. many conditions that affect the female reproductive tract, such as , sexually transmitted diseases, fungal & bacterial infections, cancer and various pathogens such as virus (human immunodeficiency virus, HIV), bacteria (Gardnerella vaginalis), fungi (Candida spp.) or parasites (Trichomonas vaginalis). Systemically active drugs (contraceptive steroids) as well as locally active drugs (metronidazole Zidovudine, Lamivudine) can be effectively delivered for an extended period of time by the help of intra-vaginal controlled release system. Continuous infusion of drugs through vaginal mucosa results in the reduced possibilities of Hepatic- gastrointestinal first-pass metabolism, gastric impatience of drugs and vacillation of dosing interval. Current study focus on the, use of various polymers which are used in hydrogels, these polymers provide bioadhesive property to the vaginal formulations, so that the vaginal formulation remains on vaginal tissues for 3- 4 days. Currently available vaginal dosage forms have several limitations, such as leakage and messiness necessitating the need to develop novel drug delivery systems.
APA, Harvard, Vancouver, ISO, and other styles
4

Bhowmik, Debjit, K. P. Sampath Kumar, and Lokesh Deb. "Buccal Drug Delivery System-A Novel Drug Delivery System." Research Journal of Science and Technology 8, no. 2 (2016): 90. http://dx.doi.org/10.5958/2349-2988.2016.00012.7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chavhan, Sarin A., Sushilkumar A. Shinde, Sandip B. Sapkal, and Vinayak N. Shrikhande. "Herbal excipients in Novel Drug Delivery Systems." International Journal of Research and Development in Pharmacy & Life Sciences 6, no. 3 (April 2017): 2597–605. http://dx.doi.org/10.21276/ijrdpl.2278-0238.2017.6(3).2597-2605.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dhiman, Jasmine. "Novel Drug Delivery System: Brief Review." Journal of Drug Delivery and Therapeutics 13, no. 11 (November 15, 2023): 188–96. http://dx.doi.org/10.22270/jddt.v13i11.6023.

Full text
Abstract:
Current developments in our knowledge of the pharmacokinetic and pharmacodynamics behaviour of drugs provide a more logical framework for designing the best possible drug delivery system. It is understandable that multidisciplinary efforts will play a major role in the success of drug delivery research in the future. Any therapeutic agent that has the potential to be safer, more effective, and use an enhanced drug delivery mechanism offers pharmaceutical companies significant marketing prospects as well as advancements in the treatment of illnesses. Since ancient times, humans have utilized plants as food and medicine, viewing them as nature's solutions. The underlying idea is that every sickness has a remedy that is concealed in better ways using ayurvedic, homeopathic and allopathic. However, in order to promote sustained release, improve patient compliance, etc., the way herbal medications are delivered must also be modified. Because of challenges with processing, standardizing, extracting, and identifying them, herbal medications had historically been unable to draw scientists' attention to the development of novel drug delivery methods. However, with today's technological advancements, the development of herbal revolutionary drug delivery systems is made possible by novel drug delivery systems (NDDS). It is possible to achieve protection against toxicity, stability enhancement, enhanced bioavailability, and protection against chemical and physical degradation of herbal formulations through the application of advanced procedures which must give the result in better or faster way. In this review we will get the method of preparations of NDDS and the Application of NDDS. Keywords: Herbal Drugs, Enhanced drug delivery, Phytosomes, Nanoparticles, liposomes.
APA, Harvard, Vancouver, ISO, and other styles
7

Malik, Mohit Saini Jitender K. "Novel Drug Delivery System Microsphere: A Review." SAR Journal of Anatomy and Physiology 3, no. 2 (April 29, 2022): 9–16. http://dx.doi.org/10.36346/sarjap.2022.v03i02.001.

Full text
Abstract:
The concept of targeted drug delivery is designed to attempt to concentrate the drug in the tissues of interest while reducing the relative concentration of the drug in the remaining tissues. As a result, the drug is localized to the targeted site. Therefore, the surrounding tissues are not affected by the drug. Therefore, carrier technology provides an intelligent approach to drug delivery by coupling drugs to carrier particles such as microspheres, nanoparticles, liposomes, niosomes, etc., modulating the release and absorption characteristics drug revenue. Microspheres are typically free-flowing powders made of proteins or synthetic polymers that are biodegradable in nature and ideally have a particle size of less than 200 μm. It is a reliable way to deliver drugs to the target site with specificity, if altered, and to maintain the desired concentration at the site of interest without side effects. Microspheres have received a great deal of attention not only for sustained release but also for targeting anti-cancer drugs to tumors. In the future, by combining various strategies, microspheres will occupy a central place in the delivery of new drugs, especially in the classification of diseased cells, diagnostics, genes and genetic material, safe, targeted and effective in vivo delivery and supplements in miniature versions of diseased organs and tissues in the body.
APA, Harvard, Vancouver, ISO, and other styles
8

Sadab, Sadab, Sarad Sahu, Shubham Patel, Rubeena Khan, Basant Khare, Bhupendra Singh Thakur, Anushree Jain, and Prateek Kumar Jain. "A Comprehensive Review: Transdermal Drug Delivery System: A Tool For Novel Drug Delivery System." Asian Journal of Dental and Health Sciences 2, no. 4 (December 15, 2022): 40–47. http://dx.doi.org/10.22270/ajdhs.v2i4.24.

Full text
Abstract:
In the recent decade, skin delivery (topical and transdermal) has gained an unprecedented popularity, especially due to increased incidences of chronic skin diseases, demand for targeted and patient compliant delivery and interest in life cycle management strategies among pharmaceutical companies. Transdermal drug delivery system was presented to overcome the difficulties of drug delivery especially oral route. Transdermal drug delivery refers to a means of delivering drugs through the surface of the skin for local or systemic treatment. The drug functions after absorption through the skin into the systemic circulation via capillary action at a certain rate. Transdermal patches are now widely used as cosmetic, topical and transdermal delivery systems. These patches represent a key outcome from the growth in skin science, technology and expertise developed through trial and error, clinical observation and evidence-based studies that date back to the first existing human records. A transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through skin and into the bloodstream. An advantage of a transdermal drug delivery route over other types of delivery system such as oral, topical, intravenous (i.v.), intramuscular (i.m.), etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive. The main disadvantage to transdermal delivery systems stems from the fact that the skin composition offers very effective barrier that allow only small molecule based drugs to penetrate the skin and pass through the barrier. Sildenafil citrate (SLD) is a selective cyclic guanosine monophosphate-specific phosphodiesterase type 5 inhibitor used for the oral treatment of erectile dysfunction and more recently, it has been used for the treatment of pulmonary arterial hypertension and the enhancement of uteroplacental perfusion in case of fetal growth retardation. The challenges facing the oral administration of the drug include poor bioavailability and short duration of action that requires frequent administration. The main objective of transdermal drug delivery system is to deliver drugs into systemic circulation through skin at predetermined rate with minimal inter and intrapatient variations. Keyword: Skin delivery, Transdermal drug delivery, Oral rout, Sildenafil citrate, Pulmonary arterial hypertension
APA, Harvard, Vancouver, ISO, and other styles
9

Chahar, Rajeev Kumar, Chanchal Tiwari, Princy Malik, and PANKAJ KUMAR JAISWAL. "Brain-Targeted Drug Delivery System: A Novel Approach." Journal of Drug Delivery and Therapeutics 12, no. 6 (November 15, 2022): 171–78. http://dx.doi.org/10.22270/jddt.v12i6.5776.

Full text
Abstract:
A targeted drug delivery system is based on a technique that continuously administers a predetermined dosage of a therapeutic agent to a sick location of the body. The targeted drug delivery goal is to raise the relative amount of the treatment in the target tissues while lowering it in the non-target tissues. This technique's intrinsic benefit has been reduced drug dose and adverse effects. Drug targeting in the brain is one of the most challenging issues in pharmaceutical research because the blood-brain barrier acts as an impermeable barrier for systemically delivered therapeutics and the brain extracellular matrix contributes to the poor distribution of locally delivered drugs. In the treatment of various Central nervous system (CNS) diseases, general approaches that can improve drug delivery to the brain are of great interest. Drugs are less harmful and more effective when they are administered close to where they would be most effective. Extreme research studies have recently concentrated on the development of fresh strategies for more successfully delivering medications to the brain in response to the shortcomings of the traditional delivery mechanism. This study thoroughly explains the obstacles involved in brain-targeted drug delivery, the process of drug transfer through Blood Brain Barrier, different techniques for brain-targeted drug delivery, and some recent breakthroughs in brain-targeted drug delivery. Keywords: Blood-brain barrier, Brain-targeted, Cerebrospinal fluid, Nanoparticles, Liposomes, Convection-enhanced drug delivery.
APA, Harvard, Vancouver, ISO, and other styles
10

Raj, Hans, Shagun Sharma, Ankita Sharma, Kapil Kumar Verma, and Amit Chaudhary. "A Novel Drug Delivery System: Review on Microspheres." Journal of Drug Delivery and Therapeutics 11, no. 2-S (April 15, 2021): 156–61. http://dx.doi.org/10.22270/jddt.v11i2-s.4792.

Full text
Abstract:
Microspheres are multiparticulate drug delivery systems that are designed to deliver drugs to a particular location at a fixed rate. Microspheres are free-flowing powders made up of biodegradable proteins or synthetic polymers with particle sizes ranging from 1 to 1000µm. Benefits of the use of microspheres in fields such as drug delivery, bone tissue manufacturing, and the absorption and desorption of contaminants by regeneration. The study shows the method of planning and measurement of microsphere parameters. Microspheres are complex, such as bioadhesive microspheres, polymeric microspheres, magnetic microspheres, floating microspheres, radioactive microspheres. Microspheres may be used in various fields such as cosmetics, oral drug delivery, target drug delivery, ophthalmic drug delivery, gene delivery, and others listed in the study. In order to achieve optimal therapeutic effectiveness, it is important to deliver the agent to the target tissue at an optimum level within the right timeframe, resulting in little toxicity and minimal side effects. There are different approaches to supplying the medicinal drug to the target site in a continuous managed manner. One such strategy is the use of microspheres as drug carriers. In this article, the value of the microsphere is seen as a novel drug delivery carrier to achieve site-specific drug delivery was discussed. Keywords: microspheres, method of preparations, polymer, bioadhesion, types of microspheres
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Novel drug delivery system"

1

Blackwell, Lisa Jane. "Sporopollenin exines as a novel drug delivery system." Thesis, University of Hull, 2007. http://hydra.hull.ac.uk/resources/hull:7162.

Full text
Abstract:
Microcapsules are fast becoming the most successful delivery systems for the oral delivery of drugs and food additives. Since many drugs are proteins and are destroyed in acidic conditions, microcapsules offer protection against the harsh environment of the gastrointestinal (GI) tract. Although the use of microcapsules achieves controlled release of the inner material, many synthetically designed microcapsules lack consistency in their size and morphology. The outer coat (exine) of plant pollen grains and spores is composed of the material sporopollenin. Sporopollenin exines (25µm diameter) were extracted from Lycopodium clavatum and were investigated as a novel drug delivery system that was inexpensive, non-toxic, from a renewable source, and exhibited a large internal cavity for loading of hydrophobic and hydrophilic substances. They showed many advantages over conventional microcapsules, including their constant chemical structure and size within a species, and their ability to offer UV and air-oxidation protection. Previous studies have shown that particles such as pollen, spores and starch migrate into the bloodstream following ingestion by a process termed 'Persorption'. Such findings intrigued many researchers but the phenomenon has not been unanimously accepted. This research is a body of evidence giving unequivocal confirmation that spores of Lycopodium clavatum and their emptied exines were absorbed into the bloodstream of man to the same extent following oral ingestion, with a maximum of 10% (± 2%) of the dose recovered just 15-30 minutes after ingestion. These findings resolve the debate between researchers in support of persorption and those against, whom doubted the transport of particles of micron size into the bloodstream, but did not disprove such a phenomenon. An extensive study was undertaken to investigate the effect of factors such as gender, age, quantity and the method of ingestion on the rate and extent of exine absorption into the bloodstream. In a preliminary in vivo experiment the successful delivery of fish oil into the bloodstream via sporopollenin exines was illustrated. A major breakthrough has formed the foundations of this research. Although sporopollenin exhibits incredible stability to organIc and inorganic solvents, in contrast, this research has shown that exines degrade very rapidly in blood plasma both in vitro and in vivo. In vitro experiments were conducted in an attempt to characterise the specific mechanism responsible for exine degradation. Progression of work has provided much evidence that the conversion of plasminogen to the enzyme plasmin is either partially or wholly responsible for the characteristic degradation of sporopollenin in the blood. Further investigations showed that it was possible to load a sufficient quantity of substances into sporopollenin exines, such as human growth hormone (hGH) , Enfurvitide (an antiretroviral agent used in the treatment of AIDS) and Cyclosporine (an antifungal agent). Their successful release from exines into different media in vitro and in vivo (carried out in Beagle dogs) was shown. These in vivo experiments highlighted the need for extra protection of the drug from the GI tract and additional coatings were applied to sporopollenin exines, including a soluble form of sporopollenin. Exines with coatings were assessed to ensure they were still able to degrade in blood and release the encapsulated substance. Current results are highly indicative that sporopollenin could become a practicable oral delivery system for molecules that are otherwise problematic to administer, such as protein drugs that degrade rapidly in acidic conditions.
APA, Harvard, Vancouver, ISO, and other styles
2

Salvage, Jonathan Peter. "A novel phosphorylcholine-based nanoparticulate drug delivery system." Thesis, University of Brighton, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.499068.

Full text
Abstract:
Phosphorylcholine (PC) based materials have been shown to have increased biocompatibility when compared to more established bio-implantable materials. This has been attributed to the ability of PC to mimic the cell lipid bilayer membrane, resulting in reduced protein adhesion and cellular interaction / activation. PC research has previously focused on the areas of contact lens formulation and medical device coating. This project sought to harness the biomimetic properties of PC to develop novel systems for drug delivery, with the emphasis being focused on microparticulate drug delivery.
APA, Harvard, Vancouver, ISO, and other styles
3

MODICA, DE MOHAC Laura. "Novel Drug Delivery System for Treatment-Resistant Schizophrenia." Doctoral thesis, Università degli Studi di Palermo, 2021. http://hdl.handle.net/10447/478483.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Campbell, K. C. "Novel systems for transdermal drug delivery." Thesis, Queen's University Belfast, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.368758.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mawad, Damia Graduate School of Biomedical Engineering Faculty of Engineering UNSW. "Development of Novel hydrogels for protein drug delivery." Awarded by:University of New South Wales. Graduate School of Biomedical Engineering, 2005. http://handle.unsw.edu.au/1959.4/25221.

Full text
Abstract:
Introduction: Embolic agents are used to block blood flow of hypervascular tumours, ultimately resulting in target tissue necrosis. However, this therapy is limited by the formation of new blood vessels within the tumour, a process known as angiogenesis. Targeting angiogenesis led to the discovery of anti-angiogenic factors, large molecular weight proteins that can block the angiogenic process. The aim of this research is development of poly (vinyl alcohol) (PVA) aqueous solutions that cross-link in situ to form a hydrogel that functions as an embolic agent for delivery of macromolecular drugs. Methods: PVA (14 kDa, 83% hydrolysed), functionalised by 7 acrylamide groups per chain, was used to prepare 10, 15, and 20wt% non-degradable hydrogels, cured by UV or redox initiation. Structural properties were characterised and the release of FITCDextran (20kDa) was quantified. Degradable networks were then prepared by attaching to PVA (83% and 98 % hydrolysed) ester linkages with an acrylate end group. The effect on degradation profiles was assessed by varying parameters such as macromer concentration, cross-linking density, polymer backbone and curing method. To further enhance the technology, radiopaque degradable PVA was synthesised, and degradation profiles were determined. Cell growth inhibition of modified PVA and degradable products were also investigated. Results: Redox initiation resulted in non-degradable PVA networks of well-controlled structural properties. Increasing the solid content from 10 to 20wt% prolonged the release time from few hours to ~ 2 days but had no effect on the percent release, with only a maximum release of 65% achieved. Ester attachment to the PVA allowed flexibility in designing networks of variable swelling behaviors and degradation times allowing ease of tailoring for specific clinical requirements. Synthesis of radiopaque degradable PVA hydrogels was successful without affecting the polymer solubility in water or its ability to polymerize by redox. This suggested that this novel hydrogel is a potential liquid embolic with enhanced X-ray visibility. Degradable products had negligible cytotoxicity. Conclusion: Novel non-degradable and radiopaque degradable PVA hydrogels cured by redox initiation were developed in this research. The developed PVA hydrogels showed characteristics in vitro that are desirable for the in vivo application as release systems for anti-angiogenic factors.
APA, Harvard, Vancouver, ISO, and other styles
6

Babu, Kavitha Mary Vadakkel. "The Development of a Novel Controlled Release Drug Delivery System." The University of Waikato, 2007. http://hdl.handle.net/10289/2590.

Full text
Abstract:
The aim of this research was to formulate, characterise and assess the feasibility of a novel drug delivery system known as the in situ gelling matrix (ISGM) where a hydrophilic polymer is suspended in a non-aqueous solvent that converts into a gel when injected subcutaneously or intramuscularly thus giving a controlled release matrix for a drug. Although the concept has been patented with claims that this kind of drug delivery is achievable in theory for a wide variety of candidate substances, actual formulation studies for making a commercially viable product for this technology are completely lacking in practice. The research embodied in this thesis addresses this lack. Initial studies involved conducting a biocompatibility study using the HET-CAM (hens egg test - chorioallantoic membrane) test on a range of possible ingredients for the delivery system. The materials deemed biocompatible were then carried through to a screening process where the physical stability of the hydrophilic polymers in non-aqueous solvents was monitored. It was found that the hydrophilic polymers tested sedimented rapidly in the non-aqueous solvents indicating such a system was not physically stable. Consequently, density-inducing or viscosity-inducing agents were added to the non-aqueous solvents to retard the sedimentation rate. The addition of polycarbophil, a viscosity-inducing agent, clearly increased the viscosity of the system. However, undesirable formation of polycarbophil globules occurred during the manufacturing process, which caused batch-to-batch variations in the viscosity of the continuous phase. Various manufacturing methods were tested before arriving at the optimum procedure to prevent globule formation using a high speed dispersion tool. A final physical sedimentation analysis of candidate continuous phases and hydrophilic polymers was conducted for determining the ideal combination of ingredients to use in the system. These investigations finally led to the adoption of an optimum mix of components consisting of 10% (w/w) hydroxypropyl methylcellulose (HPMC) (the hydrophilic polymer) suspended in a continuous phase of propylene glycol (the non-aqueous solvent) containing 0.67% (w/w) polycarbophil (the viscosity inducing agent). Using this mix of components, the in situ gelling matrix system was then subjected to various characterisation studies including infrared (IR), differential scanning calorimetry (DSC), ultraviolet-visible (UV-Vis) spectrophotometry and redispersion studies. The chemical stability of the hydrophilic polymer and the continuous phase (the non-aqueous solvent and polycarbophil) was monitored and were found to be chemically stable over a 9 month period. The feasibility of the in situ gelling matrix technology as a controlled release device was assessed using the drug propranolol. In vitro drug release studies were conducted using a custom-built dissolution apparatus. The effect of various parameters such as the concentration of the hydrophilic gelling agent on the drug release rate was investigated. Increasing the concentration of the gelling agent in the formulation resulted in a slower rate of release. The drug release data were modelled using the Higuchi relationship and a power law relationship to compare the effects of the various parameters on the release rate Stability studies on the drug in the in situ gelling matrix system were carried out by storing samples in accelerated ageing conditions of 40 C / 75% relative humidity for 4 weeks. During this time, the samples were analysed each week by high performance liquid chromatography (HPLC). These demonstrated that no apparent drug degradation had occurred over the 4-week period. This indicates that the drug propranolol in the in situ gelling matrix system is stable under ambient conditions for at least 4 weeks. The results of this study demonstrated that the in situ gelling matrix technology is potentially viable as a drug delivery system and provide a practical methodology for the commercial development of such systems.
APA, Harvard, Vancouver, ISO, and other styles
7

Sy, Jay Christopher. "Novel strategies for cardiac drug delivery." Diss., Georgia Institute of Technology, 2011. http://hdl.handle.net/1853/39531.

Full text
Abstract:
The American Heart Association (AHA) estimates that at least one American will die from a coronary event every minute, costing over $150 billion in 2008 alone. Regenerating the myocardium of patients that survive the initial infarction has proven to be an elusive goal. A variety of factors - including the loss of contractile cells, inflammatory response following infarction, cardiac hypertrophy, and lack of suitable cues for progenitor cells - causes fibrosis in the heart and loss of cardiac function. This dissertation examines three drug delivery strategies aimed at improving conditions for cardiac regeneration: polyketal microspheres as non-inflammatory drug delivery vehicles; surface functionalization of microparticles with nitrilotriacetic acid-nickel (NTA-Ni) for non-covalent tethering of proteins; and using Hoechst-inspired ligands for targeting extracellular DNA in necrotic tissue.
APA, Harvard, Vancouver, ISO, and other styles
8

Venugopal, Balaji. "Preclinical evaluation of a novel drug delivery system for cisplatin." Thesis, University of Glasgow, 2012. http://theses.gla.ac.uk/4198/.

Full text
Abstract:
The aim of this body of work was to characterise a novel cisplatin drug delivery system and to develop new tools based on biophotonic imaging that could be used to enhance studies of drug delivery in vivo. Cucurbiturils (CB) are macrocycles which are formed by acid catalysed condensation of glycoluril and formaldehyde. The internal cavity of CB[7] encapsulates a single molecule of cisplatin and the hypothesis was that encapsulation would reduce thiol degradation of the drug. Drug sensitivity studies in vitro with the cisplatin-sensitive human ovarian cancer cell line, A2780, and a cisplatin-resistant derivative, A2780/cp70, showed that the CB[7] encapsulated cisplatin retained activity but that this encapsulation drug delivery system was not able to overcome resistance to platinum. However, when these cell lines were grown as subcutaneous xenografts in nu/nu mice, the encapsulated cisplatin was able to reduce the growth of A2780/cp70 tumours which are resistant to the maximum tolerated dose of cisplatin in vivo. One possible explanation of this observation is that encapsulation might alter the pharmacokinetics of cisplatin and a method for the detection of platinum in biological samples by ICP-MS was established and validated. This assay was sufficiently sensitive to detect the low levels of platinum present in mouse plasma 24 hours after administration of either free or encapsulated cisplatin. Plasma and tissue pharmacokinetics show that encapsulation had no effect on the peak plasma concentration of cisplatin but did reduce the rate at which cisplatin was cleared from the plasma. The increased plasma AUC of cisplatin resulted in a non-selective increase in the delivery of cisplatin to both tumour and normal tissues. However, there was no apparent increase in toxicity which could be explained by the fact that encapsulation, unlike an increase in the dose of free cisplatin, had no effect on the peak plasma concentration. Subcutaneous xenografts lack critical features of human tumours. The development of more complex models for use in drug development has been limited due to lack of a method for monitoring tumour growth. Biophotonic imaging was, therefore, investigated to determine whether it is sufficiently sensitive and reproducible to be able to evaluate growth of disseminated tumours in mice. The bioluminescent signal is dependent on the metabolism of luciferin by luciferase. Subcutaneous injection of luciferin was shown to produce a consistent signal in all injected mice. The bioluminescent signal was transient but reached a maximum intensity 6 minutes after injection and remained stable for about 4 minutes which defined the window during which measurements were taken. Sensitivity was shown to be dependent on the level of expression of luciferase by the cells. Injection of commercially available HCT116Luc cells, where the luciferase gene was inserted by a lentiviral system, was shown to allow detection of 10,000 cells in the lungs of mice. This sensitivity was about 10 fold greater than was obtained by lipofectamine based gene transfection. When HCT116Luc cells were grown as subcutaneous xenografts in mice, an exponential growth pattern was easily detected by bioluminescence imaging and the reproducibility between mice was comparable to that routinely obtained by calliper measurements. Activity of encapsulated cisplatin was determined in a model of disseminated ovarian cancer. Rab25, a member of the RAS oncoprotein superfamily, is up-regulated in around 80% of ovarian cancer samples compared to normal ovarian epithelium. Rab25 contributes to tumour progression by enabling the tumour cells to invade the extracellular matrix by altering the trafficking of integrin. Transfection of Rab25 into A2780 cells results in cells that can grow in the peritoneal cavity of mice. A2780-Rab25 cells were 4 fold resistant to cisplatin in vitro which confirms a previous observation that Rab25 expression in A2780 makes them less sensitive to the induction of apoptosis in response to stress. A2780-Rab25 cells that express the luciferase gene (A2780-Rab25Luc) were injected into the peritoneal cavity of mice and growth was measured by biophotonic imaging. Exponential growth was clearly apparent at a stage at which no obvious abdominal distension was apparent. The disseminated A2780-Rab25Luc tumour xenografts were less sensitive to cisplatin than are subcutaneous xenografts of A2780. This is the first study that suggests that Rab25 over-expression results in reduced drug sensitivity in vivo. In contrast, a very significant growth inhibition was observed when mice were treated with an equivalent dose of encapsulated cisplatin regardless of whether it was administered by the intraperitoneal or subcutaneous route. These results are very encouraging since they confirm the enhanced activity of encapsulated cisplatin and also demonstrate the value of biophotonic imaging for measurement of tumour growth in vivo. Pharmacodynamic measures of drug activity in vivo in animal models are often based either on measures of surrogate tissue response or on single measures on tumour tissue removed at the end of the experiment. Biophotonic imaging in vivo allows the translation of reporter assays used in cell lines in vitro to studies of tumour response in vivo. A plasmid was prepared that links the p53 transcriptional response element to the luciferase gene and it was then transfected in to A2780 cells which express wild type p53. Stable transfectants of A2780p53Luc were treated with cisplatin, doxorubicin and paclitaxel and induction of p53 determined by bioluminescence and confirmed by Western blotting. A very low bioluminescent signal was present in untreated cells and a clear dose dependent increase in bioluminescence was seen in response to all three drugs. When A2780p53Luc cells were grown as subcutaneous xenografts the bioluminescent signal was significant in untreated tumours but was markedly increased 24 hours after treatment of the mice with cisplatin. Induction of p53 in the tumours was confirmed by immunohistochemistry and this also confirmed significant expression of p53 in untreated tumours. The possible implications of these findings for the improved delivery of cisplatin are discussed.
APA, Harvard, Vancouver, ISO, and other styles
9

Svirskis, Darren. "Development of a novel drug delivery system based on conducting polymers." Thesis, University of Auckland, 2010. http://hdl.handle.net/2292/6568.

Full text
Abstract:
Controlled release systems offer advantages over conventional therapies by maintaining drug concentrations at therapeutically desired levels whilst simultaneously improving compliance. Intrinsically Conducting Polymers (ICP) are organic materials that have electrical, magnetic and optical properties usually associated with metals, whilst retaining the advantageous mechanical properties and ease of processing usually associated with polymers. A novel drug delivery system, based on the ICP polypyrrole (PPy), has been developed to provide for the controlled release of risperidone. Due to the inherent properties of ICPs, electrical stimulation can be used to alter the redox state of PPy, which in turn can modify the release rate of drug. A validated, specific, stability indicating high performance liquid chromatography (HPLC) analytical method was used to quantify drug release from PPy films. PPy was selected as the platform material for drug delivery due to its inherent conductivity, ease of preparation and apparent biocompatibility. Various anionic dopants were trialled in the preparation of PPy films - p-toluene sulfonate produced the optimal formulation (PPy-pTS). PPy-pTS films were prepared containing risperidone (8.2 % w/w). Drug release profiles could be altered by applying different electrical stimulation. The rate of drug release could be increased or decreased by applying or withholding electrical stimulation. Atomic Force Microscopy was used to investigate changes in PPy film thickness when different stimuli were applied. The highest levels of drug release were observed when PPy was reduced; this was accompanied by expansion of the film. In order to be used clinically, the films must be functional over a defined shelf life. Stability studies suggested polymer morphology altered over time, accompanied by changes in risperidone release. In general, while aging slowed the rate of risperidone release from PPy films, release rates could be altered through electrical signalling in polymer films stored for up to 4 weeks at 40 ��C. This project relied on the multidisciplinary collaboration of pharmaceutical scientists, chemists and clinicians. The described technology could be utilised for implantable drug delivery devices, where the dose could be adjusted by external signalling, optimising patient benefit to side effect ratios while simultaneously ensuring compliance.
APA, Harvard, Vancouver, ISO, and other styles
10

Gaspar, Diana Patrícia Rodrigues. "Novel strategy to produce a drug delivery system for skin regeneration." Master's thesis, Universidade da Beira Interior, 2012. http://hdl.handle.net/10400.6/1118.

Full text
Abstract:
Skin lesions are traumatic events that lead to the increase of fluid loss, infections, scarring and locally immunocompromised regions. These injuries can be caused by genetic disorders, acute trauma or even surgical interventions. In these situations, a substantial area of skin can be damaged, often without the possibility of being regenerated. Scientists have put a lot of effort in the development of suitable drug delivery systems suitable to release therapeutic molecules that are required for the initials phases of the wound healing process. Cell microencapsulation arises as an alternative approach for sustained in situ cell delivery. This technology is based on the immobilization of cells within a polymeric matrix, surrounded by a semi-permeable membrane, that isolate the encapsulated cells from the host immune system. Nonstanding, the microparticulate matrix still allows the exchange of nutrients, gases, waste and releasing of bioactive molecules, such as extracellular matrix components and growth factors secreted by cells. Nevertheless, the optimization of cell-based therapy demands the development of alternative strategies to improve cell administration. Alginate has been used for cell microencapsulation, due to its simple gelling process, excellent biocompatibility, biodegradability properties and its stability under in vivo conditions. On the other hand, nanoparticulate systems have been widely used in the biomedical field, as drug delivery devices that can improve the efficiency and widening the applications of the microencapsulation systems. Therefore, the present study aimed to develop biodegradable alginate microparticles that were used for human fibroblasts cells and chitosan nanoparticles encapsulation, in order to improve the wound healing process. To do so, two types of microparticles were firstly produced with alginate and a mixture of alginate and collagen. Subsequently, these carriers were characterized according to their size and geometry by scanning electron microscopy. Confocal images were also acquired to confirm cell encapsulation in microparticles. The cytotoxic profile of the carriers was assessed. Cell release from microparticles was observed over time after encapsulation through optical microscopic analysis. In second part of the work, chitosan nanoparticles loaded with a model protein (bovine serum albumin) were produced and were incorporated in microparticles. The encapsulation efficiency of this protein in nanoparticles was determined. Then, both the morphology and size of these nanoparticles were characterized. The results herein obtained showed that the developed microparticles and nanoparticles can be used as systems tailored for sustainable cells and drug release.
As lesões na pele são acontecimentos traumáticos que levam ao aumento da perda de fluidos, a infecções, à formação de cicatrizes e ao aparecimento de regiões imunocomprometidas. Estas feridas podem ser causadas por desordens de origem genética, traumas ou mesmo devido a cirurgias. Deste modo, uma área substancial da pele pode ser danificada, muitas vezes sem a possibilidade de regeneração. Os investigadores têm procurado desenvolver novos sistemas de entrega de drogas, de forma a acelerar o processo de cicatrização. O microencapsulamento celular surgiu recentemente como uma nova abordagem, para entrega controlada e de longa duração de agentes terapêuticos produzidos e secretados pelas próprias células, tais como componentes da matriz extracelular e factores de crescimento, os quais são essenciais para a regeneração. Esta tecnologia tem por base a imobilização de células, dentro de uma matriz polimérica rodeada por uma membrana semi-permeável. Assim, as células não são reconhecidas pelo sistema imunitário do hospedeiro e a membrana permite a difusão de nutrientes e gases para o interior da matriz e a saída das moléculas bioactivas secretadas pelas células e dos resíduos resultantes do metabolismo celular. No entanto, a terapia celular necessita ainda de ser optimizada. O alginato é um polímero que tem sido usado para o encapsulamento celular, devido ao seu fácil processo de gelificação, excelente biocompatibilidade, biodegradabilidade e estabilidade in vivo. Por outro lado, os sistemas nanoparticulados têm sido amplamente utilizados em aplicações biomédicas, por exemplo na produção de dispositivos de entrega direcionada de moléculas bioactivas, uma vez que permitem obter um perfil de libertação controlado. O presente trabalho teve como objectivo o desenvolvimento de micropartículas de alginato para encapsular fibroblastos humanos e nanopartículas de quitosano, com o intuito de futuramente serem usadas como agentes promotores da cicatrização de feridas. Inicialmente, foram produzidos dois tipos de micropartículas, um à base de alginato e outro de alginato com colagénio. As micropartículas produzidas foram caracterizadas quanto ao seu tamanho e geometria por microscopia electrónica de varrimento. Posteriormente, foram também adquiridas imagens de confocal para confirmar o encapsulamento de células nas micropartículas. O perfil citotóxico dos transportadores foi caracterizado através de testes de viabilidade celular, os quais confirmaram a biocompatibilidade dos transportadores. O perfil de libertação das células foi observado por análise microscópica ao longo dos dias. Numa segunda parte do trabalho foram produzidas nanopartículas de quitosano com o objetivo de serem incorporadas nas micropartículas como transportadores de factores de crescimento e, assim, favorecer a cicatrização das feridas. A eficiência de encapsulação das nanopartículas foi avaliada através da incorporação de uma proteína modelo, albumina de soro bovino. Posteriormente fez-se a caracterização da morfologia e do tamanho destas nanopartículas. Os estudos efectuados demonstraram que o sistema desenvolvido é adequado para a libertação de células e moléculas bioativas de forma controlada, prolongada e em concentrações fisiológicas.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Novel drug delivery system"

1

Chien, Yie W. Novel drug delivery systems. 2nd ed. New York: M. Dekker, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gupta, Madhu, Durgesh Nandini Chauhan, Vikas Sharma, and Nagendra Singh Chauhan, eds. Novel Drug Delivery Systems for Phytoconstituents. Boca Raton : Taylor & Francis, 2020. | “A CRC title, part of the Taylor & Francis imprint, a member of the Taylor & Francis Group, the academic division of T&F Informa plc.”: CRC Press, 2019. http://dx.doi.org/10.1201/9781351057639.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Donnelly, Ryan F., and Thakur Raghu Raj Singh. Novel Delivery Systems for Transdermal and Intradermal Drug Delivery. Chichester, UK: John Wiley & Sons, Ltd, 2015. http://dx.doi.org/10.1002/9781118734506.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Donnelly, Ryan F., and Thakur Raghu Raj Singh. Novel delivery systems for transdermal and intradermal drug delivery. Chichester, United Kingdom: John Wiley and Sons, Inc., 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Feng, Nianping, and Zhijun Yang, eds. Novel Drug Delivery Systems for Chinese Medicines. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-3444-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

F, Prescott L., and Nimmo W. S, eds. Novel drug delivery and its therapeutic application. Chichester: Wiley, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

F, Prescott L., and Nimmo W. S, eds. Novel drug delivery and its therapeutic application. Chichester: Wiley, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

T, O'Hagan Derek, ed. Novel delivery systems for oral vaccines. Boca Raton: CRC Press, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Swapna, Medda, ed. Sugar-coated liposomes: A novel delivery system for increased drug efficacy and reduced drug toxicity. San Diego: Academic Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Souto, Eliana B. Novel drug delivery approaches in dry eye syndrome therapy. New York: Nova Science Publishers, Inc., 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Novel drug delivery system"

1

Patel, Brijesh, and Hetal P. Thakkar. "Cubosomes: Novel Nanocarriers for Drug Delivery." In Nanocarriers: Drug Delivery System, 227–54. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-4497-6_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Khan, Saeed Ahmad, and Hussain Ali. "Novel Drug Delivery Systems." In Essentials of Industrial Pharmacy, 235–50. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-84977-1_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jeslin, D., Muralikrishnan Dhanasekaran, and P. Panneerselvam. "Novel drug delivery systems." In Adaptive Power Quality for Power Management Units using Smart Technologies, 297–318. Boca Raton: CRC Press, 2023. http://dx.doi.org/10.1201/9781003436461-12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mishra, Astha, K. A. Shaima, and Rakesh K. Sindhu. "Novel Drug Delivery System for Ocular Target." In Nanotechnology and Drug Delivery, 205–49. New York: Jenny Stanford Publishing, 2023. http://dx.doi.org/10.1201/9781003430407-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shah, Pranav, Rinkal Jariwala, Swinal Kapadiya, Vidya P. Sabale, Priya Patel, and Pallavi M. Chaudhari. "Niosomes: A Novel Nanometric Vesicular System for Drug Delivery." In Nanocarriers: Drug Delivery System, 201–26. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-4497-6_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Saharan, Renu, Shikha Sachdeva, Inderjeet Verma, and Suresh Kumar. "Novel Drug Delivery System Approach in Cancer Treatment." In Nanotechnology and Drug Delivery, 401–37. New York: Jenny Stanford Publishing, 2023. http://dx.doi.org/10.1201/9781003430407-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Loftsson, T., E. Stefánsson, H. Friđriksdóttir, and J. K. Kristinsson. "Novel CD-Based Drug Delivery System." In Proceedings of the Eighth International Symposium on Cyclodextrins, 407–12. Dordrecht: Springer Netherlands, 1996. http://dx.doi.org/10.1007/978-94-011-5448-2_91.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lu, Patrick Y., and Martin C. Woodle. "Delivering Small Interfering RNA for Novel Therapeutics." In Drug Delivery Systems, 93–107. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-210-6_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Yadav, Hemant K. S., and Raghad Zain Alabdin. "Nanosuspension – A Novel Drug Delivery System via Nose-to-Brain Drug Delivery." In Nasal Drug Delivery, 325–37. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-23112-4_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shaima, K. A., Astha Mishra, M. Arockia Babu, Sarita Jangra, and Rakesh K. Sindhu. "Novel Drug Delivery System for Rectal and Vaginal Targets." In Nanotechnology and Drug Delivery, 507–76. New York: Jenny Stanford Publishing, 2023. http://dx.doi.org/10.1201/9781003430407-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Novel drug delivery system"

1

Mali, Ravindra, and Javesh Patil. "Nanoparticles: A Novel Antifungal Drug Delivery System." In IOCN 2023. Basel Switzerland: MDPI, 2023. http://dx.doi.org/10.3390/iocn2023-14513.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dubey, Akash Kumar, Reena Gupta, and Bhupinder Kapoor. "Novel drug delivery system: Efficacy in Alzheimer’s disease." In THE FOURTH SCIENTIFIC CONFERENCE FOR ELECTRICAL ENGINEERING TECHNIQUES RESEARCH (EETR2022). AIP Publishing, 2023. http://dx.doi.org/10.1063/5.0165900.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wang, Xiaoliang, Hongchen Gu, and Xinyuan Zhu. "A Novel Remote Controllable Drug Delivery System Triggered by Heating From Magnetic Nanoparticles." In ASME 2009 Second International Conference on Micro/Nanoscale Heat and Mass Transfer. ASMEDC, 2009. http://dx.doi.org/10.1115/mnhmt2009-18052.

Full text
Abstract:
Target drug delivery is one of the core issues in modern medicine. Although both thermo-sensitive and magnetic drug vehicles have been developed for this purpose, reliable drug targeting is yet to achieve, because it’s hard to control local temperature in body for thermo-sensitive drugs, and it’s also difficult to control the colloidal sizes of magnetic vehicles to meet the requirements for both long-time circulation and magnetic responsibility. Here we present a new technology to solve these two problems. The drug (taxel) was combined with hyper-branched thermo-sensitive polymer and magnetic nanoparticles. Magnetic responsibility of the complex can be remotely controlled by applying an alternating magnetic field. The untreated complexes were stable in dispersion, while after exposing to the alternating magnetic filed for 5 minutes, the complexes were destabilized and deposited from dispersion quickly. Unlike the commonly used water bath, the technology present here can heat up the drug vehicles remotely from outside, which must have great potentials in the applications of magnetic or thermo-sensitive drug delivery.
APA, Harvard, Vancouver, ISO, and other styles
4

Kaur, Parmandeep, and Diptiman Choudhury. "Abstract 310: Gut microflora mediated novel oral drug delivery system." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-310.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cao, Yu, Jing Liu, Hong Ma, Jing Bai, and Chao Qi. "Novel nano drug delivery systems for hepatic tumor." In Photonics and Optoelectronics Meetings 2009, edited by Qingming Luo, Lihong V. Wang, Valery V. Tuchin, Pengcheng Li, and Ling Fu. SPIE, 2009. http://dx.doi.org/10.1117/12.844928.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Shum, Ho Cheung, Tiantian Kong, Zhou Liu, and Yang Song. "Engineering Drug Delivery Vehicles With Multiphase Microfluidics." In ASME 2013 2nd Global Congress on NanoEngineering for Medicine and Biology. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/nemb2013-93028.

Full text
Abstract:
In our work, we propose the use of multiphase microfluidics to prepare drug delivery vehicles with complex structures, such as core-shell capsules, multicompartment microspheres and nonspherical particles; by tailoring the spatial distribution of drugs, unconventional drug release profiles can be achieved. To avoid the use of harmful organic solvents, we introduce the use of aqueous two-phase systems in microfluidics to generate the emulsion templates for making these novel delivery vehicles. By manipulating the interfacial characteristics of the emulsion templates, complex structures with hydrophilic and hydrophobic compartments can be prepared for separate encapsulation and sequential release of both hydrophilic and hydrophobic drugs. We will discuss the fundamental problems that need to be addressed to generate these drug delivery vehicles and highlight their potential by demonstrating their release characteristics.
APA, Harvard, Vancouver, ISO, and other styles
7

Lueshen, Eric, Indu Venugopal, and Andreas Linninger. "Intrathecal Magnetic Drug Targeting: A New Approach to Treating Diseases of the Central Nervous System." In ASME 2013 2nd Global Congress on NanoEngineering for Medicine and Biology. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/nemb2013-93117.

Full text
Abstract:
Intrathecal (IT) drug delivery is a standard technique which involves direct injection of drugs into the cerebrospinal fluid (CSF)-filled space within the spinal canal to treat many diseases of the central nervous system. Currently, in order to reach the therapeutic drug concentration at certain locations within the spinal canal, high drug doses are used. With no method to deliver the large drug doses locally, current IT drug delivery treatments are hindered with wide drug distributions throughout the central nervous system (CNS) which cause harmful side effects. In order to overcome the current limitations of IT drug delivery, we have developed the novel method of intrathecal magnetic drug targeting (IT-MDT). Gold-coated magnetite nanoparticles are infused into a physiologically and anatomically relevant in vitro human spine model and then targeted to a specific site using external magnetic fields, resulting in a substantial increase in therapeutic nanoparticle localization at the site of interest. Experiments aiming to determine the effect of key parameters such as magnet strength, duration of magnetic field exposure, location of magnetic field, and ferrous implants on the collection efficiency of our superparamagnetic nanoparticles in the targeting region were performed. Our experiments indicate that intrathecal magnetic drug targeting and implant-assisted IT-MDT are promising techniques for concentrating and localizing drug-functionalized nanoparticles at required target sites within the spinal canal for potential treatment of diseases affecting the central nervous system.
APA, Harvard, Vancouver, ISO, and other styles
8

Guegan, Eric, Tian Davis, Thomas J. Koob, and Yvonne Moussy. "Transport Characteristics of a Novel Local Drug Delivery System Using Nordihydroguaiaretic Acid (NDGA)-Polymerized Collagen Fibers." In ASME 2007 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2007. http://dx.doi.org/10.1115/sbc2007-171428.

Full text
Abstract:
Local delivery of a drug in vivo would permit high interstitial drug concentration at the desired location without producing high systemic drug levels. Previous local drug delivery systems have included biodegradable polymer implants, hydrogels, and osmotic pumps [1]. In this paper, we describe a novel local drug delivery system using nordihydroguaiaretic acid (NDGA)-polymerized collagen fibers. NDGA collagen fibers were originally developed for use as biocompatible tendon bioprostheses [2]. The NDGA collagen fibers were loaded with either: dexamethasone, a synthetic glucocorticoid with anti-inflammatory and immunosuppressive activities; or dexamethasone 21-phosphate, a water soluble pro-drug that is converted into dexamethasone in vivo. Dexamethasone was chosen as the loading agent since experiments pairing the loaded fibers with implantable glucose sensors will be performed in the future. This may be useful for preventing inflammation around implantable glucose sensor [3]. This decrease in inflammation is expected to increase glucose sensor function and lifetime. We also determined the diffusion coefficient of dexamethasone and dexamethasone 21-phosphate in the NDGA collagen fiber. In an effort to control the rate of release of dexamethasone, the biocompatible copolymer, polylactic-co-glycolic acid (PLGA) was used to coat the fibers. The information obtained from these experiments is necessary for the future development of an optimal local delivery system of dexamethasone using NDGA collagen fibers in an effort to suppress the inflammatory response around implantable glucose sensors.
APA, Harvard, Vancouver, ISO, and other styles
9

Schmieg, Jaime, Alicia Williams, and Pavlos Vlachos. "Magnetic Drug Targeting: Drug Delivery in Large Vasculature." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-193157.

Full text
Abstract:
Magnetic drug targeting (MDT) is a novel drug delivery method with potential to dramatically revolutionize clinical approaches of the treatment of many diseases. In fact, MDT has been proposed for ailments ranging from vascular disease to cancer [1, 2]. Conventional drug delivery methods utilize large doses of medication to account for the dispersion of the drug throughout the body in the hope that a sufficient concentration of medicine arrives at the diseased site. Unfortunately, many medications can have caustic effects on healthy systems leaving patients with discomfort, weakened immunity or lowered quality of life. Alternatively, MDT aims to reduce potentially harmful global dosage levels by localizing medication at the diseased site. Additionally, magnetic drug targeting not only reduces chemicals seen by healthy areas of the body, it may provide a higher concentration of drug capable of remaining at the damaged location for a longer duration than typically seen for current treatment practices. Possibly the most important advantage of MDT is the method’s ability to enhance delivery while providing no additional invasive procedures.
APA, Harvard, Vancouver, ISO, and other styles
10

Chen, Kai. "A Novel Piezo-Driven Micro-Jet Injection System for Transdermal Drug Delivery." In ASME 2009 4th Frontiers in Biomedical Devices Conference. ASMEDC, 2009. http://dx.doi.org/10.1115/biomed2009-83020.

Full text
Abstract:
A novel piezo-driven micro-jet injection system is presented for transdermal drug delivery. The system uses an amplified piezoelectric actuator and a precision ball screw to accumulate the displacement of each pulsed injection. The device effectively eliminates the flow restrictor in the ampoule.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Novel drug delivery system"

1

Dash, Alekha K. Novel in Situ Gel Drug Delivery System for Breast Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, July 2007. http://dx.doi.org/10.21236/ada474685.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sledge, George W. Nanoparticle: Monoclonal Antibody Conjugates: A Novel Drug Delivery System in Human Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2002. http://dx.doi.org/10.21236/ada420569.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sledge, George. Nanoparticle: Monoclonal Antibody Conjugates: A Novel Drug Delivery System in Human Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2000. http://dx.doi.org/10.21236/ada393348.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Esenaliev, Rinat O. Novel Drug Delivery Technique for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, July 2002. http://dx.doi.org/10.21236/ada410175.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Esenaliev, Rinat O. Novel Drug Delivery Technique for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, July 2004. http://dx.doi.org/10.21236/ada435264.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Esenaliev, Rinat O. Novel Drug Delivery Technique for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, July 2003. http://dx.doi.org/10.21236/ada418735.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

McPhillips, D. M., M. W. Price, J. W. Gibson, and R. A. Casper. Development of an On-Demand, Generic, Drug-Delivery System. Fort Belvoir, VA: Defense Technical Information Center, August 1985. http://dx.doi.org/10.21236/ada158550.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Pflugfelder Ghanashyam S., Stephen C. Broadly Applicable Nanowafer Drug Delivery System for Treating Eye Injuries. Fort Belvoir, VA: Defense Technical Information Center, September 2014. http://dx.doi.org/10.21236/ada613401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Silva, João, Matheus Warmeling, and Rogério Pagnoncelli. Platelet-rich fibrin as a drug delivery system: a scoping review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2023. http://dx.doi.org/10.37766/inplasy2023.8.0004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kedes, Laurence H., and Lali K. Medina-Kauwe. A Novel Gene Delivery System Targeted to Breast Cancer Cells. Fort Belvoir, VA: Defense Technical Information Center, August 2002. http://dx.doi.org/10.21236/ada412193.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Novel drug delivery system' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography